<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773835</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-101</org_study_id>
    <nct_id>NCT03773835</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.</brief_title>
  <official_title>A Single-center, Open-label, Uncontrolled, and Dose-escalation Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      his single-center, open-label, uncontrolled, and dose-escalation study evaluated the safety,
      tolerability, and pharmacokinetics/pharmacodynamics of single IV dose of HSK3486 injectable
      emulsion in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea</measure>
    <time_frame>First dose of study drug on day 1</time_frame>
    <description>No movement of chest wall and cessation of end-tidal carbon dioxide waveform &gt; 15 seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety by measurement of Adverse Events</measure>
    <time_frame>First dose of study drug on day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified observer's assessment of alertness/sedation（MOAA/S）</measure>
    <time_frame>From first dose of study drug until fully alert on day 1</time_frame>
    <description>Observe the change of modified observer's assessment of alert /sedation during the whole trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index （BIS）</measure>
    <time_frame>From first dose of study drug until fully alert on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median effective dose (ED50)</measure>
    <time_frame>From first dose of study drug until fully alert on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to plasma peak concentration(Tmax)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life (t1/2z) and mean residence time (MRT)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance (CL)</measure>
    <time_frame>From the start of administration to 48 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Anesthesia</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>Mmanual IV bolus injection completed in 1 minute.</description>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or females with full capacity for civil conduct, between 18 and 49 years
             old (inclusive);

          2. Body weight &gt; 45 kg, and body mass index (BMI) ≥ 19 and ≤24 kg/m2;

          3. Blood pressure between 90-140/60-90 mmHg; heart rate between 60-99 bpm; body
             temperature between 35.8-37.5 ºC; respiration rate between 12-24 breaths per minute;
             SpO2 when inhaling &gt; 95%;

          4. Normal physical examination, laboratory tests (blood routine, blood biochemistry, and
             urine routine), 12-Led ECG, posteroanterior and lateral chest x-ray, and or abnormal
             but without clinical significance (determined by investigator); no potential difficult
             airway;

          5. Subjects must understand the procedures and methods of this study, and be willing to
             provide informed consent and to complete the trial in strict accordance with clinical
             trial protocol.

        Exclusion Criteria:

          1. Known sensitivity to propofol, excipient in propofol medium and long chain fat
             emulsion injection, excipient in HSK3486 injectable emulsion;

          2. contraindicated in general anesthesia;

          3. Received any one of the following medications or treatments prior to
             screening/enrollment:

               1. History of medication abuse or any signs of chronic benzodiazepines use (such as
                  insomnia, anxiety, spasms) within 3 months prior to screening, or a positive
                  urine medication test (during screening or at baseline);

               2. Participated in clinical trials involving any medications or medical devices
                  within 3 months prior to screening, or participated in 3 or more drug clinical
                  trials within the past year;

          4. History or evidence of increased risk of sedation or anesthesia, such as
             cardiovascular disease, respiratory disease, cerebrovascular disease,
             gastrodintestinal disease and other system disease prior to the screening and/or
             baseline period;

          5. Laboratory results that meet any of the following during screening/enrollment:

               1. Positive for HBsAg, HCV, or HIV;

               2. Abnormal hepatic or renal function confirmed after re-examination;

                    -  ALT or AST &gt; ULN;

                    -  Creatinine &gt; ULN;

          6. History of smoking for more than 3 weeks and/or respiratory irritation caused by
             smoking within 3 months prior to screening;

          7. History of alcohol abuse within 3 months prior to screening or a positive alcohol test
             (baseline);

          8. Women who are pregnant or breastfeeding; women of child-bearing potential or men who
             are unwilling to use contraception during the trial;

          9. Subjects judged by the investigator to be unsuitable for participating in this trial
             for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

